Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Douglas E. Onsi J.D. | CFO, General Counsel, Treasurer & Secretary, President, CEO & Director | 1.1M | -- | 1969 |
| Mr. Augustine J. Lawlor | Chief Operating Officer | 749.81k | -- | 1957 |
| Dr. Cynthia A. Sirard M.D. | Chief Medical Officer | 747.57k | -- | 1970 |
| Dr. Jason S. Baum Ph.D. | Chief Scientific Officer | -- | -- | 1979 |
| Mr. Mark O'Mahony | Chief Manufacturing Officer | -- | -- | 1971 |
| Ms. Christine M. Granfield | VP and Head of Regulatory Affairs & Quality | -- | -- | 1968 |
Leap Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 54
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Corporate Governance
Upcoming Events
November 13, 2024 at 12:00 PM UTC
Leap Therapeutics, Inc. Earnings Date
Recent Events
May 21, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission